



HOSPITAL AUTHORITY DRUG FORMULARY

(v16.3 - w.e.f. 9 Jan 2021) new drugs listed highlighted in "yellow" color

(Drugs newly listed in Self-financed item with Safety Net w.e.f. 29 Dec 2020)

- (1) The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand.
- (2) Some drugs may appear in more than one category due to different formulations and/or indications.
- (3) The "Special" drugs will be prescribed as clinically indicated based on the specified indications.
- (4) Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed in the HA Drug Formulary.

BNF	General Drugs	Special Drugs	Self-financed item With Safety Net	Self-financed item Without Safety Net
8	MALIGNANT DISEASE AND IMMUNOSUPPRESSION 癌瘤及免疫系統藥物			
8.1	CYTOTOXIC DRUGS			
	ACTINOMYCIN D	BLEOMYCIN	ABEMACICLIB	ATEZOLIZUMAB
	ASPARAGINASE	BLINATUMOMAB	AFATINIB	BEVACIZUMAB
	CALCIUM FOLINATE	BUSULPHAN	ALECTINIB	BORTEZOMIB
	CAPECITABINE	CETUXIMAB	ATEZOLIZUMAB	CABOZANTINIB (CABOMETYX)
	CARBOPLATIN	CLADRIBINE	AXITINIB	CARFILZOMIB
	CARMUSTINE	CLOFARABINE	AZACITIDINE	CETUXIMAB
	CHLORAMBUCIL	CRISANTASPASE (ASPARAGINASE ERW)	BENDAMUSTINE	DABRAFENIB
	CISPLATIN	DASATINIB	BEVACIZUMAB	DARATUMUMAB
	CYCLOPHOSPHAMIDE	DOCETAXEL	BORTEZOMIB	DOCETAXEL
	CYTARABINE	ERIBULIN	BRENTUXIMAB VEDOTIN	DOXORUBICIN (LIPOSOMAL)
	DACARBAZINE	ERLOTINIB	BRIGATINIB	ESTRAMUSTINE
	DAUNORUBICIN	EVEROLIMUS (AFINITOR) (OR EQUIV)	CARFILZOMIB	EVEROLIMUS (AFINITOR) (OR EQUIV)
	DOXORUBICIN	FLUDARABINE	CERITINIB	IPILIMUMAB
	EPIRUBICIN	IFOSFAMIDE	CETUXIMAB	LENVATINIB
	ETOPOSIDE	IMATINIB	CRIZOTINIB	NERATINIB
	FLUOROURACIL	MITOXANTRONE	DABRAFENIB	NIVOLUMAB
	GEMCITABINE	PEGASPARAGINASE	DASATINIB	OLAPARIB
	HYDROXYUREA	PEMETREXED	DOXORUBICIN (LIPOSOMAL)	OSIMERTINIB
	IDARUBICIN	TEMOZOLOMIDE	DURVALUMAB	PACLITAXEL (ALBUMIN)
	IRINOTECAN	TS-1 (OR EQUIV)	EVEROLIMUS (AFINITOR) (OR EQUIV)	PAZOPANIB
	LOMUSTINE	VINORELBINE	GEFITINIB	PEMBROLIZUMAB
	MELPHALAN		IBRUTINIB	PERTUZUMAB
	MERCAPTOPYRINE		IMATINIB	PONATINIB
	MESNA		INOTUZUMAB OZOGAMICIN	REGORAFENIB
	METHOTREXATE		IXAZOMIB	SORAFENIB
	MITOMYCIN		LAPATINIB	SUNITINIB
	MITOTANE		LENVATINIB	TOPOTECAN
	OXALIPLATIN		MIDOSTAURIN	TRAMETINIB
	PACLITAXEL		NILOTINIB	TRASTUZUMAB EMTANSINE
	PROCARBAZINE		NIVOLUMAB	VENETOCLAX
	THIOGUANINE		OBINUTUZUMAB	
	TRETINOIN		OSIMERTINIB	
	VINBLASTINE		PALBOCICLIB	
	VINCRIStINE		PANITUMUMAB	
			PAZOPANIB	
			PEMBROLIZUMAB	
			PERTUZUMAB	
			RIBOCICLIB	
			RUXOLITINIB	
			SORAFENIB	
			SUNITINIB	

BNF	General Drugs	Special Drugs	Self-financed item With Safety Net	Self-financed item Without Safety Net
			TEMOZOLOMIDE TRAMETINIB TRASTUZUMAB TRASTUZUMAB EMTANSINE VEMURAFENIB	
8.2	DRUGS AFFECTING THE IMMUNE RESPONSE AZATHIOPRINE BCG THALIDOMIDE	ANTITHYMOCYTE IMMUNOGLOBULIN BASILIXIMAB CYCLOSPORIN A CYCLOSPORIN A (NEORAL) CYCLOSPORIN A (TEVA) DIMETHYL FUMARATE EVEROLIMUS (CERTICAN) (OR EQUIV) FINGOLIMOD INTERFERON BETA MYCOPHENOLATE PEGINTERFERON ALFA RITUXIMAB SIROLIMUS TACROLIMUS TERIFLUNOMIDE	ALEMTUZUMAB (LEMTRADA) CANAKINUMAB INTERFERON GAMMA LENALIDOMIDE NATALIZUMAB RITUXIMAB	LENALIDOMIDE POMALIDOMIDE RITUXIMAB
8.3	SEX HORMONES AND HORMONE ANTAGONISTS IN MALIGNANT DISEASE LETROZOLE MEDROXYPROGESTERONE ACETATE MEGESTROL OCTREOTIDE SOMATOSTATIN TAMOXIFEN	ANASTROZOLE BICALUTAMIDE BUSERELIN CYPROTERONE DEGARELIX EXEMESTANE FLUTAMIDE GOSERELIN LANREOTIDE LEUPRORELIN OCTREOTIDE PASIREOTIDE TRIPTORELIN	ABIRATERONE ENZALUTAMIDE	ABIRATERONE ENZALUTAMIDE